Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Crenezumab> ?p ?o. }
Showing items 1 to 50 of
50
with 100 items per page.
- Crenezumab abstract "Crenezumab is a humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune, which licensed the drug in 2006 to Genentech, Inc. Its original name RG7412 refers to its inventor at AC Immune.In May 2012, it was announced that the efficacy of crenezumab will be tested in a five-year trial against early-onset Alzheimer's disease. The $100 million trial will be funded by Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health. Participants in the study will be recruited from an extended family in and around Medellín, Colombia. Approximately one-third of the 5,000 family members carry an autosomal dominant allele of presenilin-1 (PSEN1) that causes the early-onset form of Alzheimer's disease. The trial will test the effect of the drug on 300 individuals who have the PSEN1 mutation, but do not yet show symptoms of the disease.".
- Crenezumab atcPrefix "none".
- Crenezumab casNumber "1174395-19-7".
- Crenezumab wikiPageID "33023931".
- Crenezumab wikiPageRevisionID "546560143".
- Crenezumab atcPrefix "none".
- Crenezumab c "6442".
- Crenezumab casNumber "1174395".
- Crenezumab chemspiderid "NA".
- Crenezumab h "9966".
- Crenezumab hasPhotoCollection Crenezumab.
- Crenezumab mabType "mab".
- Crenezumab molecularWeight "144.88".
- Crenezumab n "1706".
- Crenezumab o "2018".
- Crenezumab s "40".
- Crenezumab source "zu/o".
- Crenezumab target "1".
- Crenezumab type "mab".
- Crenezumab verifiedfields "changed".
- Crenezumab verifiedrevid "458433785".
- Crenezumab subject Category:Monoclonal_antibodies.
- Crenezumab type Abstraction100002137.
- Crenezumab type Antibody115027189.
- Crenezumab type Chemical114806838.
- Crenezumab type Compound114818238.
- Crenezumab type Macromolecule114944888.
- Crenezumab type Material114580897.
- Crenezumab type Matter100020827.
- Crenezumab type Molecule114682133.
- Crenezumab type MonoclonalAntibodies.
- Crenezumab type MonoclonalAntibody115029781.
- Crenezumab type OrganicCompound114727670.
- Crenezumab type Part113809207.
- Crenezumab type PhysicalEntity100001930.
- Crenezumab type Protein114728724.
- Crenezumab type Relation100031921.
- Crenezumab type Substance100019613.
- Crenezumab type Thing100002452.
- Crenezumab type Unit109465459.
- Crenezumab type Drug.
- Crenezumab type FunctionalSubstance.
- Crenezumab comment "Crenezumab is a humanized monoclonal antibody against human 1-40 and 1-42 Beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune, which licensed the drug in 2006 to Genentech, Inc. Its original name RG7412 refers to its inventor at AC Immune.In May 2012, it was announced that the efficacy of crenezumab will be tested in a five-year trial against early-onset Alzheimer's disease.".
- Crenezumab label "Crenezumab".
- Crenezumab sameAs m.0h52wn8.
- Crenezumab sameAs Q5184156.
- Crenezumab sameAs Q5184156.
- Crenezumab sameAs Crenezumab.
- Crenezumab wasDerivedFrom Crenezumab?oldid=546560143.
- Crenezumab isPrimaryTopicOf Crenezumab.